Structure-based design and synthesis of potent, ethylenediamine-based, mammalian farnesyltransferase inhibitors as anticancer agents

Steven Fletcher, Erin Pusateri Keaney, Christopher G. Cummings, Michelle A. Blaskovich, Michael A. Hast, Matthew P. Glenn, Sung Youn Chang, Cynthia J. Bucher, Ryan J. Floyd, William P. Katt, Michael H. Gelb, Wesley C. Van Voorhis, Lorena S. Beese, Said M. Sebti, Andrew Hamilton

Research output: Contribution to journalArticle

Abstract

A potent class of anticancer, human farnesyltransferase (hFTase) inhibitors has been identified by "piggy-backing" on potent, antimalarial inhibitors of Plasmodium falciparum farnesyltransferase (PfFTase). On the basis of a 4-fold substituted ethylenediamine scaffold, the inhibitors are structurally simple and readily derivatized, facilitating the extensive structure-activity relationship (SAR) study reported herein. Our most potent inhibitor is compound 1f, which exhibited an in vitro hFTase IC50 value of 25 nM and a whole cell H-Ras processing IC50 value of 90 nM. Moreover, it is noteworthy that several of our inhibitors proved highly selective for hFTase (up to 333-fold) over the related prenyltransferase enzyme geranylgeranyltransferase-I (GGTase-I). A crystal structure of inhibitor 1a co-crystallized with farnesyl pyrophosphate (FPP) in the active site of rat FTase illustrates that the para-benzonitrile moiety of 1a is stabilized by a π-π stacking interaction with the Y361β residue, suggesting a structural explanation for the observed importance of this component of our inhibitors.

Original languageEnglish (US)
Pages (from-to)6867-6888
Number of pages22
JournalJournal of Medicinal Chemistry
Volume53
Issue number19
DOIs
StatePublished - Oct 14 2010

Fingerprint

ethylenediamine
Farnesyltranstransferase
Antineoplastic Agents
Inhibitory Concentration 50
Dimethylallyltranstransferase
Antimalarials
Plasmodium falciparum
Structure-Activity Relationship
Catalytic Domain
Enzymes

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery
  • Medicine(all)

Cite this

Structure-based design and synthesis of potent, ethylenediamine-based, mammalian farnesyltransferase inhibitors as anticancer agents. / Fletcher, Steven; Keaney, Erin Pusateri; Cummings, Christopher G.; Blaskovich, Michelle A.; Hast, Michael A.; Glenn, Matthew P.; Chang, Sung Youn; Bucher, Cynthia J.; Floyd, Ryan J.; Katt, William P.; Gelb, Michael H.; Van Voorhis, Wesley C.; Beese, Lorena S.; Sebti, Said M.; Hamilton, Andrew.

In: Journal of Medicinal Chemistry, Vol. 53, No. 19, 14.10.2010, p. 6867-6888.

Research output: Contribution to journalArticle

Fletcher, S, Keaney, EP, Cummings, CG, Blaskovich, MA, Hast, MA, Glenn, MP, Chang, SY, Bucher, CJ, Floyd, RJ, Katt, WP, Gelb, MH, Van Voorhis, WC, Beese, LS, Sebti, SM & Hamilton, A 2010, 'Structure-based design and synthesis of potent, ethylenediamine-based, mammalian farnesyltransferase inhibitors as anticancer agents', Journal of Medicinal Chemistry, vol. 53, no. 19, pp. 6867-6888. https://doi.org/10.1021/jm1001748
Fletcher, Steven ; Keaney, Erin Pusateri ; Cummings, Christopher G. ; Blaskovich, Michelle A. ; Hast, Michael A. ; Glenn, Matthew P. ; Chang, Sung Youn ; Bucher, Cynthia J. ; Floyd, Ryan J. ; Katt, William P. ; Gelb, Michael H. ; Van Voorhis, Wesley C. ; Beese, Lorena S. ; Sebti, Said M. ; Hamilton, Andrew. / Structure-based design and synthesis of potent, ethylenediamine-based, mammalian farnesyltransferase inhibitors as anticancer agents. In: Journal of Medicinal Chemistry. 2010 ; Vol. 53, No. 19. pp. 6867-6888.
@article{58e45976a736423a89ea559c1ca0e780,
title = "Structure-based design and synthesis of potent, ethylenediamine-based, mammalian farnesyltransferase inhibitors as anticancer agents",
abstract = "A potent class of anticancer, human farnesyltransferase (hFTase) inhibitors has been identified by {"}piggy-backing{"} on potent, antimalarial inhibitors of Plasmodium falciparum farnesyltransferase (PfFTase). On the basis of a 4-fold substituted ethylenediamine scaffold, the inhibitors are structurally simple and readily derivatized, facilitating the extensive structure-activity relationship (SAR) study reported herein. Our most potent inhibitor is compound 1f, which exhibited an in vitro hFTase IC50 value of 25 nM and a whole cell H-Ras processing IC50 value of 90 nM. Moreover, it is noteworthy that several of our inhibitors proved highly selective for hFTase (up to 333-fold) over the related prenyltransferase enzyme geranylgeranyltransferase-I (GGTase-I). A crystal structure of inhibitor 1a co-crystallized with farnesyl pyrophosphate (FPP) in the active site of rat FTase illustrates that the para-benzonitrile moiety of 1a is stabilized by a π-π stacking interaction with the Y361β residue, suggesting a structural explanation for the observed importance of this component of our inhibitors.",
author = "Steven Fletcher and Keaney, {Erin Pusateri} and Cummings, {Christopher G.} and Blaskovich, {Michelle A.} and Hast, {Michael A.} and Glenn, {Matthew P.} and Chang, {Sung Youn} and Bucher, {Cynthia J.} and Floyd, {Ryan J.} and Katt, {William P.} and Gelb, {Michael H.} and {Van Voorhis}, {Wesley C.} and Beese, {Lorena S.} and Sebti, {Said M.} and Andrew Hamilton",
year = "2010",
month = "10",
day = "14",
doi = "10.1021/jm1001748",
language = "English (US)",
volume = "53",
pages = "6867--6888",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "19",

}

TY - JOUR

T1 - Structure-based design and synthesis of potent, ethylenediamine-based, mammalian farnesyltransferase inhibitors as anticancer agents

AU - Fletcher, Steven

AU - Keaney, Erin Pusateri

AU - Cummings, Christopher G.

AU - Blaskovich, Michelle A.

AU - Hast, Michael A.

AU - Glenn, Matthew P.

AU - Chang, Sung Youn

AU - Bucher, Cynthia J.

AU - Floyd, Ryan J.

AU - Katt, William P.

AU - Gelb, Michael H.

AU - Van Voorhis, Wesley C.

AU - Beese, Lorena S.

AU - Sebti, Said M.

AU - Hamilton, Andrew

PY - 2010/10/14

Y1 - 2010/10/14

N2 - A potent class of anticancer, human farnesyltransferase (hFTase) inhibitors has been identified by "piggy-backing" on potent, antimalarial inhibitors of Plasmodium falciparum farnesyltransferase (PfFTase). On the basis of a 4-fold substituted ethylenediamine scaffold, the inhibitors are structurally simple and readily derivatized, facilitating the extensive structure-activity relationship (SAR) study reported herein. Our most potent inhibitor is compound 1f, which exhibited an in vitro hFTase IC50 value of 25 nM and a whole cell H-Ras processing IC50 value of 90 nM. Moreover, it is noteworthy that several of our inhibitors proved highly selective for hFTase (up to 333-fold) over the related prenyltransferase enzyme geranylgeranyltransferase-I (GGTase-I). A crystal structure of inhibitor 1a co-crystallized with farnesyl pyrophosphate (FPP) in the active site of rat FTase illustrates that the para-benzonitrile moiety of 1a is stabilized by a π-π stacking interaction with the Y361β residue, suggesting a structural explanation for the observed importance of this component of our inhibitors.

AB - A potent class of anticancer, human farnesyltransferase (hFTase) inhibitors has been identified by "piggy-backing" on potent, antimalarial inhibitors of Plasmodium falciparum farnesyltransferase (PfFTase). On the basis of a 4-fold substituted ethylenediamine scaffold, the inhibitors are structurally simple and readily derivatized, facilitating the extensive structure-activity relationship (SAR) study reported herein. Our most potent inhibitor is compound 1f, which exhibited an in vitro hFTase IC50 value of 25 nM and a whole cell H-Ras processing IC50 value of 90 nM. Moreover, it is noteworthy that several of our inhibitors proved highly selective for hFTase (up to 333-fold) over the related prenyltransferase enzyme geranylgeranyltransferase-I (GGTase-I). A crystal structure of inhibitor 1a co-crystallized with farnesyl pyrophosphate (FPP) in the active site of rat FTase illustrates that the para-benzonitrile moiety of 1a is stabilized by a π-π stacking interaction with the Y361β residue, suggesting a structural explanation for the observed importance of this component of our inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=77957896645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957896645&partnerID=8YFLogxK

U2 - 10.1021/jm1001748

DO - 10.1021/jm1001748

M3 - Article

VL - 53

SP - 6867

EP - 6888

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 19

ER -